Nebenwirkungen · Benlysta
Benlysta 120 mg powder for concentrate for solution for infusion. Benlysta 400 mg powder for concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 58
HOS-124013 · Präparat HOS-095751
In the lupus nephritis study, patients were receiving a background of standard therapy (see section 5.1) and the overall incidence of infections was 82 % in patients receiving Benlysta compared with 76 % in patients receiving placebo. Serious infections occurred in 13.8 % of patients receiving Benlysta and in 17.0 % of patients receiving placebo. Fatal infections occurred in 0.9 % (2/224) of patients receiving Benlysta and in 0.9 % (2/224) of patients receiving placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T14:51:00Z · SHA-256 c5a3f583695e2640a8d21bbd8da1102adfb181d1d2a9c5afe0028436c8fd2402 · Passage 8870f457b22544f79f0e4f70b81992669bbc83c8074131af9ee1c4786c771e97 · Zeichen 7772–8246 im Abschnitt